Emory University School of Medicine, Cleveland, Ohio.
Department of Quantitative Health Sciences, Cleveland, Ohio.
J Thorac Cardiovasc Surg. 2023 Mar;165(3):1111-1121.e12. doi: 10.1016/j.jtcvs.2021.04.065. Epub 2021 Apr 29.
Left ventricular assist devices require a psychosocial assessment to determine candidacy despite limited data correlating with outcome. Our objective is to determine whether the Stanford Integrated Psychosocial Assessment for Transplant, a tool validated for transplant and widely used by left ventricular assist device programs, predicts left ventricular assist device program hospital readmissions and death.
We performed a retrospective analysis of adults at the Cleveland Clinic with Stanford Integrated Psychosocial Assessment for Transplant scores before primary left ventricular assist device program implantation from April 1, 2013, to December 31, 2018. The primary outcome was unplanned hospital readmissions censored at death, transplantation, and transfer of care. The secondary outcome was death.
There were 263 patients in the left ventricular assist device program with a median (Q1, Q3) Stanford Integrated Psychosocial Assessment for Transplant score of 16 (8, 28). During a median follow-up 1.2 years, 56 died, 65 underwent transplantation, and 21 had transferred care. There were 640 unplanned hospital readmissions among 250 patients with at least 1 outpatient visit at our center. In a multivariable analysis, Stanford Integrated Psychosocial Assessment for Transplant components but not total Stanford Integrated Psychosocial Assessment for Transplant score was associated with readmissions. Psychopathology (Stanford Integrated Psychosocial Assessment for Transplant C-IX) was associated with hemocompatibility (coefficient 0.21 ± standard error 0.11, P = .040) and cardiac (0.15 ± 0.065, P = .02) readmissions. Patient readiness was associated with noncardiac (Stanford Integrated Psychosocial Assessment for Transplant A-III, 0.24 ± 0.099, P = .016) and cardiac (Stanford Integrated Psychosocial Assessment for Transplant A-low total, 0.037 ± 0.014, P = .007) readmissions. Poor living environment (Stanford Integrated Psychosocial Assessment for Transplant B-VIII) was associated with device-related readmissions (0.83 ± 0.34, P = .014). Death was associated with organic psychopathology or neurocognitive impairment (Stanford Integrated Psychosocial Assessment for Transplant C-X, 0.59 ± 0.21, P = .006).
Total Stanford Integrated Psychosocial Assessment for Transplant score was not associated with left ventricular assist device program readmission or mortality. However, we identified certain Stanford Integrated Psychosocial Assessment for Transplant components that were associated with outcome and could be used to create a left ventricular assist device program specific psychosocial tool.
尽管与结果相关的数据有限,但左心室辅助设备需要进行社会心理评估以确定候选资格。我们的目的是确定斯坦福综合移植社会心理评估是否可以预测左心室辅助设备计划的住院再入院和死亡,该工具已通过移植验证,并被广泛用于左心室辅助设备计划。
我们对 2013 年 4 月 1 日至 2018 年 12 月 31 日在克利夫兰诊所接受首次左心室辅助设备计划植入的成年人进行了回顾性分析,这些患者具有斯坦福综合移植社会心理评估得分。主要结局是计划外住院再入院,死亡,移植和护理转移均被删失。次要结局是死亡。
在左心室辅助设备计划中有 263 例患者,中位(Q1,Q3)斯坦福综合移植社会心理评估得分为 16(8,28)。在中位随访 1.2 年期间,有 56 人死亡,65 人接受了移植,21 人转移了护理。在我们中心至少有 1 次门诊就诊的 250 名患者中,共有 640 例计划外住院再入院。在多变量分析中,斯坦福综合移植社会心理评估的组成部分,但不是斯坦福综合移植社会心理评估的总分与再入院有关。精神病理学(斯坦福综合移植社会心理评估 C-IX)与血液相容性(系数 0.21±标准误差 0.11,P=0.040)和心脏(0.15±0.065,P=0.02)再入院有关。患者准备情况与非心脏(斯坦福综合移植社会心理评估 A-III,0.24±0.099,P=0.016)和心脏(斯坦福综合移植社会心理评估 A-低总,0.037±0.014,P=0.007)再入院有关。较差的生活环境(斯坦福综合移植社会心理评估 B-VIII)与器械相关的再入院有关(0.83±0.34,P=0.014)。死亡与有机精神病理学或神经认知障碍(斯坦福综合移植社会心理评估 C-X,0.59±0.21,P=0.006)有关。
斯坦福综合移植社会心理评估的总分与左心室辅助设备计划的再入院或死亡率无关。但是,我们确定了某些与结果相关的斯坦福综合移植社会心理评估的组成部分,这些组成部分可用于创建专门用于左心室辅助设备计划的社会心理工具。